about
Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.GABA System in Schizophrenia and Mood Disorders: A Mini Review on Third-Generation Imaging StudiesThe power of using functional fMRI on small rodents to study brain pharmacology and diseaseThe antipsychotic potential of muscarinic allosteric modulationAnimal models of neuropsychiatric disordersDelayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice.Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice.NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.Neurophysiological biomarkers for drug development in schizophrenia.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.Sex-dependent behavioral effects and morphological changes in the hippocampus after prenatal invasive interventions in rats: implications for animal models of schizophrenia.Treatments in context: transcranial direct current brain stimulation as a potential treatment in pediatric psychosisEffect of second-generation antipsychotics on cognition: current issues and future challenges.Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia.Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.New paradigms for treatment development.Effects of Subchronic Phencyclidine (PCP) Treatment on Social Behaviors, and Operant Discrimination and Reversal Learning in C57BL/6J Mice.Expression profiles of schizophrenia susceptibility genes during human prefrontal cortical developmentGenome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations.The pharmacogenetics of symptom response to antipsychotic drugs.D₁ receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test.
P2860
Q24633622-CE766FE8-F793-4884-8629-4B7444C02287Q24649568-C2F76528-FB46-4CD0-B112-CC3434E19C27Q26752657-FCB04D38-27E8-4250-A59D-0C22BFA696E0Q26779671-E4406DE5-986E-4836-82BD-D262A3EF9420Q28603221-4708A159-207D-43C9-A12E-3DA16192F887Q29619899-22B58E33-3FA8-495B-9BF3-455483D71594Q30443234-8D580A8A-41D3-41D9-B862-AD43B1ADCDFCQ30448782-C0CE0176-FCBD-4F7D-938C-0EC19FAE567EQ30465008-04E384A0-33A3-479B-BEBF-183397A5FF33Q30486447-4F5D2304-1C11-4B61-9FB0-DBE3CB6E1EDCQ30489404-1540340B-B5CC-4F70-AA28-169106F35F74Q30493072-75844865-EA00-40BB-B80B-42EE257844BAQ33684720-A3782E94-F6A4-4CFA-BB1E-BAA82260C7C0Q33778750-677438DE-D15F-4A45-BF98-24C5B2B9732CQ33888153-17E65340-D5D8-47A2-A4C2-5F44065AAA29Q34096784-6F7EA3FF-76E1-4DDE-9C5E-1B9DFACE3F30Q34350145-AC15F6DA-E793-4DF9-AFBE-DBED5CD755A5Q34660546-280B6AEA-B3D7-4685-9DCE-E65907A24494Q35417493-912AE908-725E-4EBD-A4EB-7711DF3FE6BAQ36935148-BD3E78C8-AB26-49F4-B4AD-959E670861F2Q37076137-182DB942-5A2A-4644-982D-6959D309C20FQ37112450-E67622AA-71EB-4471-B549-CB15BBD46D53Q37438984-48D4AF5C-C492-4E65-974D-6302866DDC7DQ37563079-FACF05F8-2E2F-4F03-BAF0-88AC98363FECQ41500882-BAB50988-2EE0-4F5E-BBE7-6F982895C87EQ44543014-578C2705-A9FC-40F2-8617-601091603E7E
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The neurobiology of cognition in schizophrenia.
@ast
The neurobiology of cognition in schizophrenia.
@en
type
label
The neurobiology of cognition in schizophrenia.
@ast
The neurobiology of cognition in schizophrenia.
@en
prefLabel
The neurobiology of cognition in schizophrenia.
@ast
The neurobiology of cognition in schizophrenia.
@en
P1476
The neurobiology of cognition in schizophrenia
@en
P2093
Carol A Tamminga
P304
9-13; discussion 36-42
P478
67 Suppl 9
P577
2006-01-01T00:00:00Z